Yanqiao Ren1,2, Lei Chen1,2, Songjiang Huang1,2, Chen Zhou1,2, Jiacheng Liu1,2, Qin Shi1,2, Chongtu Yang1,2, Renwang Chen3, Chuansheng Zheng1,2, Ping Han4,5, Bin Xiong6,7. 1. Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. 2. Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China. 3. Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. 4. Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. cjr.hanping@vip.163.com. 5. Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China. cjr.hanping@vip.163.com. 6. Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. herr_xiong@126.com. 7. Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China. herr_xiong@126.com.
Abstract
PURPOSE: The purpose of this study was to evaluate the therapeutic efficacy and safety of transarterial chemoembolization (TACE) in the treatment of patients with unresectable colorectal cancer liver metastases (CRCLM) who had failed systemic chemotherapy. In addition, the role of TACE in the treatment of CRCLM is also worth discussing. METHODS: This single-center retrospective study evaluated the consecutive medical records of patients with CRCLM treated with TACE from June 2014 to June 2018, who had failed at least two lines of prior chemotherapy. Therapeutic response, overall survival (OS), progression-free survival (PFS), and complications were recorded. RESULTS: Fifty-three eligible patients were included in our study. The objective tumor radiologic regression and disease control rates were 52.8% and 79.2%, respectively. Median OS and PFS were 15 months (95% confidence interval [CI] 13.1 months, 16.9 months) and 6 months (95% CI 4.7 months, 7.3 months), respectively. Multivariate analysis found that synchronous metastatic disease, presence of extrahepatic metastasis, and Child-Pugh score B were independent prognostic factor for OS and PFS. Two patients (3.8%) had severe complications. The results of subgroup analysis showed that synchronous liver metastasis and extrahepatic metastasis had an effect on the prognosis of patients, while the primary tumor sites (rectum, left, and right colon) had no effect on the prognosis. CONCLUSIONS: TACE is well tolerated and effective in patients with unresectable chemotherapy refractory CRCLM. Meanwhile, the results of this study also indicated that TACE is still a better treatment for these patients.
PURPOSE: The purpose of this study was to evaluate the therapeutic efficacy and safety of transarterial chemoembolization (TACE) in the treatment of patients with unresectable colorectal cancer liver metastases (CRCLM) who had failed systemic chemotherapy. In addition, the role of TACE in the treatment of CRCLM is also worth discussing. METHODS: This single-center retrospective study evaluated the consecutive medical records of patients with CRCLM treated with TACE from June 2014 to June 2018, who had failed at least two lines of prior chemotherapy. Therapeutic response, overall survival (OS), progression-free survival (PFS), and complications were recorded. RESULTS: Fifty-three eligible patients were included in our study. The objective tumor radiologic regression and disease control rates were 52.8% and 79.2%, respectively. Median OS and PFS were 15 months (95% confidence interval [CI] 13.1 months, 16.9 months) and 6 months (95% CI 4.7 months, 7.3 months), respectively. Multivariate analysis found that synchronous metastatic disease, presence of extrahepatic metastasis, and Child-Pugh score B were independent prognostic factor for OS and PFS. Two patients (3.8%) had severe complications. The results of subgroup analysis showed that synchronous liver metastasis and extrahepatic metastasis had an effect on the prognosis of patients, while the primary tumor sites (rectum, left, and right colon) had no effect on the prognosis. CONCLUSIONS:TACE is well tolerated and effective in patients with unresectable chemotherapy refractory CRCLM. Meanwhile, the results of this study also indicated that TACE is still a better treatment for these patients.
Authors: K Malagari; H Moschouris; Th Kiakidis; S Harward; A Kelekis; S Vrakas; D Koundouras; D Filipiadis; G Glantzounis; E Emmanouil; A Chatziioannou; V Vergadis; I Elefsiniotis; J Koskinas; S Dourakis; N Kelekis Journal: Cardiovasc Intervent Radiol Date: 2019-07-18 Impact factor: 2.740
Authors: Giammaria Fiorentini; Camillo Aliberti; Massimo Tilli; Luca Mulazzani; Francesco Graziano; Paolo Giordani; Andrea Mambrini; Francesco Montagnani; Paolo Alessandroni; Vincenzo Catalano; Paolo Coschiera Journal: Anticancer Res Date: 2012-04 Impact factor: 2.480